ACM
WST icon

Azimuth Capital Management’s West Pharmaceutical WST Stock Holding History

Azimuth Capital Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$10.5M Sell
25,497
-22,101
-46% -$8.65M 0.45% 76
2021
Q4 		$22.3M Sell
47,598
-1,016
-2% -$437K 0.9% 26
2021
Q3 		$20.6M Sell
48,614
-309
-0.6% -$130K 0.89% 26
2021
Q2 		$17.6M Buy
48,923
+972
+2% +$321K 0.76% 39
2021
Q1 		$13.5M Buy
47,951
+545
+1% +$156K 0.64% 56
2020
Q4 		$13.4M Buy
47,406
+443
+0.9% +$124K 0.67% 45
2020
Q3 		$12.9M Sell
46,963
-34,462
-42% -$9.12M 0.76% 47
2020
Q2 		$18.5M Sell
81,425
-23,420
-22% -$4.6M 1.18% 11
2020
Q1 		$16M Buy
104,845
+339
+0.3% +$52.2K 1.2% 13
2019
Q4 		$15.7M Buy
104,506
+200
+0.2% +$29.1K 0.95% 30
2019
Q3 		$14.8M Buy
104,306
+54,352
+109% +$7.48M 0.96% 29
2019
Q2 		$6.25M Sell
49,954
-1,482
-3% -$175K 0.42% 86
2019
Q1 		$5.67M Sell
51,436
-4
-0% -$416 0.38% 93
2018
Q4 		$5.04M Buy
51,440
+235
+0.5% +$25.5K 0.39% 88
2018
Q3 		$6.32M Buy
51,205
+910
+2% +$102K 0.42% 86
2018
Q2 		$4.99M Sell
50,295
-2,070
-4% -$191K 0.36% 100
2018
Q1 		$4.62M Sell
52,365
-1,770
-3% -$166K 0.34% 113
2017
Q4 		$5.34M Sell
54,135
-1,840
-3% -$180K 0.39% 93
2017
Q3 		$5.39M Buy
55,975
+3,160
+6% +$286K 0.4% 89
2017
Q2 		$4.99M Buy
52,815
+1,275
+2% +$117K 0.39% 88
2017
Q1 		$4.21M Buy
51,540
+2,435
+5% +$204K 0.34% 97
2016
Q4 		$4.17M Buy
49,105
+1,385
+3% +$109K 0.36% 91
2016
Q3 		$3.56M Sell
47,720
-96,235
-67% -$7.64M 0.31% 104
2016
Q2 		$10.9M Sell
143,955
-985
-0.7% -$71.7K 0.98% 20
2016
Q1 		$10M Buy
144,940
+41,081
+40% +$2.47M 0.96% 23
2015
Q4 		$6.25M Buy
103,859
+4,870
+5% +$293K 0.61% 61
2015
Q3 		$5.36M Buy
98,989
+37,418
+61% +$2.18M 0.56% 65
2015
Q2 		$3.58M Buy
61,571
+1,605
+3% +$89.6K 0.35% 100
2015
Q1 		$3.61M Buy
59,966
+1,580
+3% +$84.2K 0.35% 98
2014
Q4 		$3.11M Buy
58,386
+830
+1% +$41.5K 0.32% 101
2014
Q3 		$2.58M Buy
57,556
+711
+1% +$30.2K 0.28% 109
2014
Q2 		$2.4M Buy
+56,845
New +$2.43M 0.27% 118

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Azimuth Capital Management's WST Position: Q1 2022 in Review

Azimuth Capital Management reduced its West Pharmaceutical (WST) stake by 46% in Q1 2022, selling an estimated $8.65M and leaving 25,497 shares worth $10.5M. The position accounts for 0.45% of the portfolio, ranked #76.

Azimuth Capital Management first reported a position in WST in Q2 2014 and has held it in 32 quarters since. The position peaked at $22.3M in Q4 2021. 717 funds tracked by Wall St. Rank hold WST as of Q1 2022.

  • Azimuth Capital Management held 25,497 shares of West Pharmaceutical worth $10.5M as of Q1 2022.
  • Azimuth Capital Management sold 22,101 West Pharmaceutical shares in Q1 2022, an estimated $8.65M.
  • West Pharmaceutical made up 0.45% of Azimuth Capital Management's portfolio in Q1 2022, its #76 holding.
  • Azimuth Capital Management first reported a position in West Pharmaceutical in Q2 2014 and has held it in 32 quarters since.
  • Azimuth Capital Management's West Pharmaceutical position peaked at $22.3M in Q4 2021.
  • 717 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2022.

Based on Azimuth Capital Management's 13F filing for Q1 2022, filed 13 May 2022.